Idenix Pharmaceuticals and Swiss drug maker Novartis said telbivudine, their experimental drug for hepatitis B, met its primary goal in a Phase III trial. The 1,350-patient study showed telbivudine was at least as effective as lamivudine, the standard Hepatitis B treatment, after one year of use. The companies said they plan to ask US regulators for approval by the end of 2005.
- read this press release for more